Evolution of the consumption of lorazepam in a rural environment in the Region of Murcia (2012-2018)

Evolution of the consumption of lorazepam in a rural environment in the Region of Murcia (2012-2018)

Show other versions (1)

Objective: To evaluate the consumption of lorazepam in the Region of Murcia, specifically in the district of Mula, during the period 2012-2018, considering age and sex variables. Method: Cross-sectional descriptive study, where the use of benzodiazepines in a specific population during the period...

Full description

Bibliographic Details
Main Authors:	Juan Antonio Cano-Hernández, Pura Ballester, Sandra Sierra-Alarcón, Alejandro Galindo-Tovar
Format:	Article
Language:	English
Published:	Fundación Pharmaceutical Care España 2022-08-01
Series:	Pharmaceutical Care España
Subjects:	Benzodiazepines, Pharmaceutical care, Primary Health care, Anxiolytic, Anxiety
Online Access:	https://www.pharmcareesp.com/index.php/PharmaCARE/article/view/777

Similar Items

Evolution of the consumption of lorazepam in a rural environment in the Region of Murcia (2012-2018)
by: Juan Antonio Cano-Hernández, et al.
Published: (2022-08-01)

Clinical practice for unspecified anxiety disorder in primary care
by: Hitoshi Sakurai, et al.
Published: (2023-09-01)

Characteristics of patients with anxiety disorder without selective serotonin reuptake inhibitor prescription over a two‐year period of pharmacotherapy
by: Keisuke Mori, et al.
Published: (2024-03-01)

Linalool Odor-Induced Anxiolytic Effects in Mice
by: Hiroki Harada, et al.
Published: (2018-10-01)

Management of unspecified anxiety disorder: Expert consensus
by: Hitoshi Sakurai, et al.
Published: (2023-06-01)

Comparison of perception of stress and consumption of anxiolytics in hospital and out-hospital conditions: a cross-sectional study
by: Željko Jovanović, et al.
Published: (2024-02-01)

Herbal medicines as a safe alternative to synthetic anxiolytics in the treatment of stress and anxiety among servicemen
by: O. O. Dobrovolnyi, et al.
Published: (2024-12-01)

A Comparison of the Anxiolytic Properties of Tofisopam and Diazepam: A Double-Blind, Randomized, Crossover, Placebo-Controlled Pilot Study
by: Andrzej Kokoszka
Published: (2024-01-01)

Development and acceptability of a decision aid for anxiety disorder considering discontinuation of benzodiazepine anxiolytic
by: Yumi Aoki, et al.
Published: (2023-05-01)

Quality of Life Assessment in Patients Using Benzodiazepines during the COVID-19 Pandemic in a Community Pharmacy Using EuroQol 5D-3L
by: Daida Alberto Armas, et al.
Published: (2023-01-01)

Use of anxiolytics and hypnotic drugs during COVID-19 pandemic: The literature review
by: Trajkovski Tea, et al.
Published: (2022-01-01)

Sunshine hours and utilization of benzodiazepines
by: Marković Srđan Z., et al.
Published: (2021-01-01)

Different Attitudes of Patients and Psychiatrists Toward Benzodiazepine Treatment
by: Kawamata Y, et al.
Published: (2021-06-01)

Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects
by: Cheng T, et al.
Published: (2018-05-01)

8-Substituted Triazolobenzodiazepines: In Vitro and In Vivo Pharmacology in Relation to Structural Docking at the α1 Subunit-Containing GABAA Receptor
by: Lalit K. Golani, et al.
Published: (2021-04-01)

Assessment of dependence and anxiety among benzodiazepine users in a provincial municipality in Rio Grande do Sul, Brazil
by: Janaína Barden Schallemberger, et al.

Risk Characterization in Patients Using Benzodiazepines While Providing Pharmaceutical Care Dispensing Service
by: Daida Alberto Armas, et al.
Published: (2024-07-01)

Malignant catatonia responsive to low doses of lorazepam: case report
by: Diego Fernando Moreira Matias, et al.

Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review
by: Mario Amore, et al.
Published: (2021-02-01)

Lorazepam-induced short-term remission of symptoms in a case of paranoid schizophrenia
by: Shubhangi R Parkar, et al.
Published: (2011-01-01)

The brain decade in debate: II. Panic or anxiety? From animal models to a neurobiological basis
by: R. Andreatini, et al.
Published: (2001-02-01)

Anxiolytic-like effects of 4-phenyl-2-trichloromethyl-3H-1,5-benzodiazepine hydrogen sulfate in mice
by: M.A. Rubin, et al.
Published: (2000-09-01)

Clinical effects of central antagonist of cholecystokinin-1 receptors GB-115 in patients with Generalized Anxiety Disorder
by: O. Dorofeeva, et al.
Published: (2022-06-01)

Comparative Efficacy of Lorazepam and Risperidone in Hospitalized Cannabis-induced Psychotic Disorder
by: Arshdeep Jhalli, et al.
Published: (2024-02-01)

A Comparative Study of the Clinical Efficacy and Safety of Lorazepam and Chlordiazepoxide in Alcohol Dependence Syndrome
by: Ranjani Ramanujam, et al.
Published: (2015-03-01)

Oral clonazepam versus lorazepam in the treatment of methamphetamine-poisoned children: a pilot clinical trial
by: Fariba Farnaghi, et al.
Published: (2020-12-01)

Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health
by: R. Kathryn McHugh, et al.
Published: (2023-03-01)

Analysis of changes in trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs
by: Miguel Angel Fernández García, et al.
Published: (2018-12-01)

Plants and phytochemicals potentials in tackling anxiety: A systematic review
by: Nasiri Phootha, et al.
Published: (2022-11-01)

Cognitive status and use of analgesics and anxiolytics in residents of nursing homes in the Czech Republic
by: Holmerová I, et al.
Published: (2018-12-01)

Pharmacology of human experimental anxiety
by: F.G. Graeff, et al.
Published: (2003-04-01)

Addressing the Issue of Chronic, Inappropriate Benzodiazepine Use: How Can Pharmacists Play a Role?
by: Helen C. Gallagher
Published: (2013-09-01)

Anxiolytic and sedative effects of sodium valproate with different experimental paradigms in male and female rats
by: María de losÁngeles Cintado, et al.
Published: (2024-12-01)

A Systematic Review of the Efficacy of Compression Wraps as an Anxiolytic in Domesticated Dogs
by: Savannah Mathis, et al.
Published: (2024-11-01)

Pilot Study on the Efficacy and Safety of Long-Term Oral Imepitoin Treatment for Control of (Thunder)Storm-Associated Noise Phobia/Noise Aversion in Dogs Using an Individualized-Dose Titration Approach
by: Ana C. Muñoz Amezcua, et al.
Published: (2024-02-01)

Impact of central antagonist of cholecystokinin-1 receptors GB-115 on cognitive functions in patients with Generalized Anxiety Disorder
by: O. Dorofeeva, et al.
Published: (2022-06-01)

Investigating the potential of the anti-epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsy
by: Rowena M. A. Packer, et al.
Published: (2017-04-01)

Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties
by: Lara Sharpe, et al.
Published: (2020-10-01)

Chronic use of diazepam in primary healthcare centers: user profile and usage pattern
by: Carmen Sylvia Ribeiro, et al.

The Effects of <i>Echinacea</i> (EP107<sup>TM</sup>) on Anxiety: A Comparison of Anxiety Measures in a Randomized, Double Blind, Placebo-Controlled Study
by: József Haller, et al.
Published: (2025-02-01)